top of page
Sage Group News
SAJE Pharma - An Opportunity to Access A Unique and Powerful Multi-Drug Discovery Platform Focused o
SAJE Pharma (www.sajepharma.com) seeks an acquirer or licensee of its GSNORi (S-nitrosoglutathione reductase inhibitor) drug discovery...
Zora Offers Cardiovascular / Diabetes and Ovarian Cancer Risk Prevention Tests
Zora Biosciences (“Zora”; www.zora.fi) is a privately funded, Finnish-based diagnostics company with novel intellectual property and a...
Opportunity for Leadership in Predictive Biomarker Diagnostics for Pre-Eclampsia
Metabolomic Diagnostics (“MetaDx”; www.metabolomicdiagnostics.com) is a Cork, Ireland-based predictive biomarker diagnostics company with...
Sage Advises Vesselon on Partnering Its Microbubble Technology for Improving Delivery of Cancer Drug
Sage has been appointed by Vesselon based in Norwalk Connecticut USA. Vesselon uses patents from Columbia University on the use of...
Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy
Sage is representing Mateon Therapeutics, a US-based biopharma company focusing on Vascular Disrupting Agents (VDAs) for orphan oncology...
Opportunity to License or Acquire ES-3000, An Orphan Drug for CML and AML
Escend Therapeutics (www.escendpharma.com) is based in San Diego, CA, and develops small molecule therapeutics for oncology orphan drug...
Sage Group Advises APR on InLicensing and Acquisition of Novel Pharma Products
ABOUT APR Applied Pharma Research s.a. (www.apr.ch; “APR” or the “Company”) is a profitable, well-financed, privately held, Swiss...
Sage Advises Solasia on a Global Partnership for Darinaparsin, a Novel Treatment for Peripheral T Ce
Solasia has engaged The Sage Group to manage a program to establish a global partnership regarding licensing of its Darinaparsin product...
bottom of page